Universidad Autonoma de Madrid
Quick facts
Phase 3 pipeline
- Cultured Mesenchymal Stem Cells · Regenerative Medicine / Immunology
Cultured mesenchymal stem cells promote tissue repair and regeneration through immunomodulation, anti-inflammatory signaling, and differentiation into replacement cells.
Phase 2 pipeline
- Cultured autologous Mesenchymal Cells · Immunology
Cultured autologous Mesenchymal Cells are thought to exert their therapeutic effects through immunomodulation and tissue repair.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Universidad Autonoma de Madrid portfolio CI brief
- Universidad Autonoma de Madrid pipeline updates RSS
Frequently asked questions about Universidad Autonoma de Madrid
What is Universidad Autonoma de Madrid's pipeline?
Universidad Autonoma de Madrid has 1 drugs in Phase 3, 1 in Phase 2, 1 in Phase 1. Late-stage candidates include Cultured Mesenchymal Stem Cells.
Related
- Sector hub: All tracked pharma companies